Allogeneic mesenchymal stem cells therapy - Bonus BioGroup
Alternative Names: MesenCureLatest Information Update: 05 Mar 2025
At a glance
- Originator Bonus BioGroup
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID-19 pneumonia
- Phase II SARS-CoV-2 acute respiratory disease
- Preclinical Cytokine release syndrome; Inflammation
- No development reported Adult respiratory distress syndrome; Pneumonia
Most Recent Events
- 20 Feb 2025 US FDA approves IND application for MesenCure™ in Adult respiratory distress syndrome
- 28 May 2024 No recent reports of development identified for preclinical development in Adult-respiratory-distress-syndrome in Israel (IV, Infusion)
- 28 May 2024 No recent reports of development identified for preclinical development in Pneumonia in Israel (IV, Infusion)